A systematic review identified nursing tips for the care of pediatric patients at risk of cytokine release syndrome after blinatumomab or CAR-T therapy.
CHIP was associated with higher rates of complete response and cytokine release syndrome.
A report examines a newly created role in nursing care for managing patient care during chimeric antigen receptor T-cell therapy in the outpatient setting.
Researchers sought to determine whether CAR-T therapy would be an effective treatment for patients with relapsed/refractory multiple myeloma.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
